Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156090 | 1.00 | CARM1 (0.56) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL4569287 | 0.98 | CARM1 (0.58) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL13787914 | 0.93 | CARM1 (0.52) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL25736046 | 0.90 | CARM1 (0.48) | CARM1PRMT6PRMT8CA12CA1 | |
| SCHEMBL12309176 | 0.86 | HRH3 (0.52) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL18568453 | 0.86 | HRH3 (0.52) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL16311941 | 0.85 | HRH3 (0.56) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL10574951 | 0.85 | CARM1 (0.50) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL18782445 | 0.85 | CARM1 (0.50) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL8258583 | 0.84 | CARM1 (0.48) | CARM1PRMT6PRMT8HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
| EP-3135672-A1 | COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES | VM Discovery, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2356109-B1 | COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES | VM DISCOVERY INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1444201-B1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LTD (GB) | 2007-09-12 | — | — | EP | disclosed |
| US-7179835-B2 | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2007-02-20 | — | — | US | disclosed |
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | US | disclosed |
| EP-1444201-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003043981-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | IRF3, BCL3, L3MBTL3 | CARM1 388/4885PRMT6 1279/4885PRMT8 1861/4885 |
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | SERPINC1, F11, SERPINE1 | CARM1 4763/4885PRMT6 2400/4885PRMT8 2510/4885 |
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | CARM1 2297/4885PRMT6 3271/4885PRMT8 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.